Mads Hald Andersen

46PUBLICATIONS
149CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersGene and molecular therapySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Sep 07, 2026
Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.

|Apr 10, 2026
Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.

Mads Hald Andersen

|Mar 24, 2026
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.

Josephine Hallundbæk Ruders, Shamaila Munir Ahmad, Rasmus Erik Johansson Mortensen

|Dec 14, 2025
Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Sidsel Pedersen, Mikkel Byrdal, Evelina Martinenaite

|Nov 17, 2025
β-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cells.

Klaire Yixin Fjæstad, Astrid Zedlitz Johansen, Hannes Linder

|Jun 14, 2025
Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer.

Terkild B Buus, Chella Krishna Vadivel, Maria Gluud

Pageof 8

Frequent Collaborators

9 joint publications

Morten Orebo Holmström

9 joint publications

Inge Marie Svane

7 joint publications

Maria Perez-Penco

5 joint publications

Özcan Met